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ABSTRACT
Introduction The burden of post- tuberculosis (TB) lung 
disease (PTBLD) is steadily increasing in sub- Saharan 
Africa, causing disability among TB survivors. Without 
effective medicines, the mainstay of PTBLD treatment 
evolves around disease prevention and supportive 
treatment. Pulmonary rehabilitation (PR), a low- cost, non- 
pharmacological intervention has shown effectiveness 
in a group of PTBLD individuals but has not been tested 
in a clinical trial. This study aims to assess the impact of 
a 6- week PR programme on maximal exercise capacity 
and other outcomes among adults in Uganda living with 
PTBLD.
Methods and analysis This is a randomised waiting- list 
controlled trial with blinded outcome measures, comparing 
PR versus usual care for patients with PTBLD. A total 
of 114 participants will be randomised (1:1) to receive 
either usual care (on the waiting list) or PR, with follow- up 
assessments at 6 weeks and 12 weeks postintervention. 
The primary outcome is change in walking distance 
measured by the Incremental Shuttle Walk Test from 
baseline to the end of 6 weeks of PR. All secondary 
outcomes will be compared between the PR and usual 
care arms from baseline to 6- week and 12- week follow- 
ups. Secondary outcomes include self- reported respiratory 
symptoms, physical activity, psychological well- being, 
health- related quality of life and cost–benefit analysis. All 
randomised participants will be included in the intention- 
to- treat analysis population. The primary efficacy analysis 
will be based on both per- protocol and modified intention- 
to- treat populations.
Ethics and dissemination The trial has received ethical 
clearance from the Mulago Hospital Research and Ethics 
Committee (MHREC 1478), Kampala, Uganda as well as 
the Uganda National Council for Science and Technology 
(SS 5105). Ethical approval has been obtained from the 
University of Leicester, UK research ethics committee (Ref 
No. 22349). Study findings will be published in appropriate 
peer- reviewed journals and disseminated at appropriate 
local, regional and international scientific meetings and 
conferences.
Trial registration number ISRCTN18256843.
Protocol version Version 1.0 July 2019.
INTRODUCTION
Background and rationale
In 2018, 24% of the global Tuberculosis 
(TB) incident cases occurred in the African 
region.1 Furthermore, 24 of the 30 high TB/
HIV burden countries, including Uganda, 
are in the African region; accounting for 71% 
of the global burden of HIV associated TB.1 
Despite great strides made over the recent 
years to achieve the 90% treatment success 
rate, as part of the ‘End TB strategy’ target,1 a 
significant number of TB survivors continue 
to have poor health- related quality of life 
(HRQoL).2 This may be attributed to the 
pulmonary function impairment following 
TB treatment, which has been reported in 
Strengths and limitations of this study
 ► The study aims to determine the effectiveness of 
pulmonary rehabilitation (PR) for individuals with 
post- tuberculosis lung disease (PTBLD) in a clini-
cal trial setting. To our knowledge, this is the first 
pragmatic, fully powered effectiveness trial for PR 
in PTBLD in Africa. This is a progression of previous 
work that established feasibility and acceptability of 
PR design for people living with PTBLD in Uganda.
 ► Due to funding limitations, we are unable to carry 
out a multi- site study. This may limit generalisability 
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approximately 50% of pulmonary TB survivors.3 The 
reduction in ventilation and perfusion attributed to the 
permanent lung parenchymal damage4 clinically mani-
fests as long- term respiratory symptoms and eventually 
chronic respiratory disease (CRD), including chronic 
obstructive pulmonary disease (COPD), bronchiectasis 
and aspergillosis.5 6
Adults with post- TB respiratory symptoms develop 
skeletal muscle dysfunction, related to physical inactivity 
and systemic inflammation, which is often compounded 
by impaired nutrition and poverty.7 Such patients enter 
a vicious cycle with falling body weight, progressive 
morbidity and increased mortality.7 Individuals affected 
by CRDs tend to avoid exercise and become increasingly 
deconditioned and demotivated, leading to a cycle of 
decline. There are no effective medicines for post- TB 
lung disease (PTBLD) and the mainstay of treatment 
evolves around disease prevention and supportive treat-
ment. The disease, previously neglected by health services 
and researchers, is now the focus of increasing interest.8 9
In low- income and middle- income countries (LMIC) 
where healthcare focuses on treatment and prevention 
of infectious diseases, as opposed to managing chronic 
diseases, the care for adults living with CRD presents a 
major challenge. Consequently, patients that require 
long- term and systemic approaches often receive sub- 
optimal medical care, inevitably leading to preventable 
deaths in resource poor settings.
Pulmonary Rehabilitation (PR) is a low cost, high 
impact intervention that reverses the disability associ-
ated with CRDs, and is supported by the highest level of 
research evidence in high- income countries.10 11 A PR 
programme brings together health professionals from 
many disciplines offering supervised exercise training 
and disease education, supporting people to manage 
their own disease. However, in LMIC where the burden 
of CRDs is increasing fastest, PR is scarce and healthcare 
services are poorly adapted to deal with such diseases. 
Although PR is a grade ‘A’ evidence treatment for adults 
with COPD12 and has been used in other chronic lung 
diseases,13 its efficacy in PTBLD is not known. In a devel-
opment study to examine the impact of PR for people with 
PTBLD in Uganda, it was feasible to run a PR programme 
and participants reported clinically important improve-
ments in quality of life, exercise capacity and respiratory 
outcomes.14 To date, there has been little attention to the 
role of PR in PTBLD globally, particularly in Africa where 
a significant number of PTB survivors reside.
Study objectives
The primary objective of this trial is to assess the impact 
of a 6- week PR programme on maximal exercise capacity 
using the incremental shuttle walking test (ISWT) among 
adults living with PTBLD postintervention.
The secondary objectives include assessing the impact 
of PR on quality of life and other outcomes for patients 
with PTBLD, and to conduct a cost–benefit analysis of PR.
METHODS
Study design
This is a prospective, randomised waiting- list controlled 
trial with blinded outcome measures, comparing PR 
versus usual care for patients with PTBLD. During this 
effectiveness trial, a total of 114 participants will be 
Figure 1 Figure showing the study flow in the post- TB pulmonary rehabilitation (PR) trial. PTBLD, post- TB lung disease; R&A, 
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randomised (1:1) to receive either usual care (waiting- 
list) or PR (figure 1).
Study setting
The study is conducted at the PR centre located at 
the Makerere University Lung Institute (MLI) Clinic, 
Kampala, Uganda. The MLI clinic is an academic outpa-
tient clinic within the Mulago National Referral hospital, 




Adults with PTBLD will be referred from health facilities 
and clinics (TB treatment centres and HIV/TB caring 
centres) around Kampala to the PR centre. Existing 
registers have around 300 adults living with PTBLD and 
additional patients will be screened directly from the 
outpatient departments.
In this study, a patient is considered to have PTBLD if 
they successfully completed treatment for microbiolog-
ically confirmed pulmonary TB but continue to expe-
rience chronic respiratory symptoms with radiological 
evidence of lung parenchymal damage.
Participant invitation
The process of identifying and inviting eligible patients 
was refined in the development study. Eligible individuals 
identified as having an established PTBLD diagnosis will 
be received at the PR centre at the MLI. Literate partici-
pants will be asked to read the patient information sheet 
(PIS) about the study, written in English or translated in 
the local language. Illiterate participants will have the 
contents read to them in full by a study staff, in the pres-
ence of a witness who will be present during the whole 
process. Participants will have the opportunity to discuss 
the PIS with the study medical personnel. Once the study 
staff are satisfied that the participant has understood the 
PIS, and is interested in taking part in the study, they will 
be taken through the informed consent process. Partici-
pants will give consent before undergoing screening tests 
and procedures, and if still eligible after the screening 




A patient with PTBLD is eligible for the trial if they meet 
all of the following criteria: aged ≥18 years, willing and 
able to provide written informed consent (signed or 
witnessed consent if the patient is illiterate), a docu-
mented history of smear positive pulmonary TB with 
treatment completed ≥6 months prior to study enrol-
ment, a negative Xpert MTB/RIF assay for Mycobacterium 
tuberculosis at the time of study enrolment, and report a 
Medical Research Council (MRC) dyspnoea grade ≥2.
Exclusion criteria
A PTBLD patient is ineligible for the study if they have 
co- morbidities that preclude exercise (eg, known unstable 
cardiovascular disease, locomotor difficulties) or if they 
are unwilling to participate for any reason or had any 
condition (social or medical) which in the opinion of the 
investigator would make study participation unsafe.
Randomisation
Once eligible participants have consented to take part 
in the study, they will be randomised using a web- based 
randomisation system (https://www. sealedenvelope. 
com/). Participants will be randomised (1:1) to receive 
either usual care or PR. Access to the web- based system 
will be controlled through an authorised username and 
password. Randomisations will be conducted by a member 
of the study team independent from the data collection 
team and will be revealed to the data collection and inter-
vention delivery teams after baseline measurements have 
been obtained.
Participant timeline
After randomisation, the PR team will explain to partici-
pants when the PR sessions will take place. For each indi-
vidual participant, the hospital based PR programme will 
last 6 weeks, followed by a follow- up period of 6 weeks of 
home exercises. Participants in the control arm (waiting- 
list) of the trial will be informed of the date for their first 
exercise session in approximately 12–15 weeks. Based on 
our development study,15 we expect to find prolonged 
and possibly improved effects of PR at follow- up. Our 
experience indicates that a follow- up period of more 
than 3 months after the start of the PR programme would 
be unrealistic in this environment without unacceptable 
attrition. Study participants will receive compensation for 
their time and transport.
PR team
The PR team has received adequate training on the 
delivery of PR and participated in the development study 
which informed this trial.14 Furthermore, the individ-
uals are registered health professionals (physiotherapist, 
physicians and nurses) and have undertaken training 
regarding the study tests, procedures and measurements 
per protocol as well as Good Clinical Practice.
Assessment and follow-up
Participants in both arms of the trial will be asked to 
attend the baseline, 6- week and 12- week postinterven-
tion assessment visits at the PR centre at MLI. Data will 
be collected by the study staff (medical doctor, nurse and 
physiotherapist). Table 1 shows all baseline and follow- up 
assessment data that will be collected during the trial, in 
accordance with a minimum recommended dataset for 
PR trials in LMIC.16
Study procedures
During the screening visit, prospective participants will 
undergo clinical examination, MRC dyspnoea grading, 
sputum examination using Xpert MTB/RIF assay and 
a frontal chest radiograph. In addition, demographic, 
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respiratory symptoms and exposure history to cigarettes 
and biomass) will be collected using a standardised ques-
tionnaire. At the randomisation visit, spirometry will be 
performed using American Thoracic Society and Euro-
pean Respiratory Society guidelines.17
Sample size
The study will be powered to detect a 35 m difference 
in the ISWT measured at baseline and after completion 
of PR.18 Assuming that ISWT follows an approximately 
normal distribution, a power calculation based on a 
paired t- test was performed. Based on a trial sample size 
of 40 participants in each of the treatment and control 
groups, a two- sided 5% significance level and a statistical 
power of 80%, the clinically important change in ISWT of 
35 m will also be statistically significant. Our recent feasi-
bility study15 was used to obtain an estimate of the pooled 
SD for the power calculation. Conservatively assuming up 
to 30% losts to follow- up at 6 weeks, a total of 114 partici-
pants are required to be recruited and randomised (1:1) 
to each arm (PR: 57 participants or waiting list: 57 partic-
ipants). Using the 70% ineligibility rate during screening 
from the feasibility study, we will need to screen approxi-
mately 543 PTBLD patients.
Blinding (masking)
Due to the nature of PR, it will not be possible to blind 
participants to their group allocation but participants will 
be asked not to reveal their group during the follow- up 
assessments. The participant and treating clinician will 
be aware of treatment allocation, however, the outcome 
measures will be performed by staff blinded to treatment 
allocation and the ISWT (primary outcome) will be prior-
itised to reduce the risk of un- blinding. Any episodes of 
unblinding will be documented and reported.
Treatment arms
Usual care (control arm)
The participants in the waiting- list (control) arm will 
receive usual care and will be offered PR after completing 
12 weeks of follow- up. There are currently no guidelines 
for the clinical management of PTBLD both locally 
and internationally. Usual care will be optimised where 
possible and will include the following: frontal chest 




12 weeks of study participation
Hospital based 
pulmonary rehab
Follow- up phase of 
homebased exercises
End of 6 weeks of PR
End of 6 weeks of 
home exercises
Written informed consent x x     
Demographics x x     
Medical history x x     
Clinical exam x x     
Chest X- ray x       
Spirometry   x     
MRC dyspnoea grade x   x x
Assess symptoms x   x x
Incremental Shuttle Walk Test x   x x
Endurance Shuttle Walk Test x   x x
Borg breathlessness scale x   x x
Mid Upper Arm Circumference x   x x
Sit- to- stand time x   x x
COPD Assessment Test   x x x
Clinical COPD Questionnaire   x x x
Patient Health Questionnaire   x x x
HADS   x x x
WPAI   x x x
Physical Activity (Actigraph monitor)   x x x
Cost/benefit analysis   x x x
EQ- 5D- 5L Questionnaire   x x x
COPD, chronic obstructive pulmonary disease; EQ- 5D- 5L, European Quality of Life 5- Dimensions; HADS, Hospital Anxiety and 
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radiograph, spirometry to screen for airway diseases, 
inhalational therapies for airway disease amenable to 
treatment (where appropriate), antibiotic and systemic 
glucocorticoid therapy for infective exacerbations 
(where appropriate), and verbal advice to quit smoking 
and reduce exposure to biomass smoke. According to 
local practice, all post- TB patients with significant post-
bronchodilator response on Spirometry (at least 12% 
and 200mls increase in forced expiratory volume in 1 s 
(FEV1)) are managed with a combination of inhaled 
corticosteroids and long- acting beta- agonists, while those 
with fixed airflow obstruction (postbronchodilator FEV1/
forced vital capacity ratio of less than 0.70) are managed 
with long acting bronchodilators. PR will be offered as 
an adjunctive non- pharmacological treatment as recom-
mended by international guidelines.19
PR (trial intervention arm)
In addition to usual care described above, participants in 
the intervention arm will receive PR. PR will consist of a 
6- week programme offered to a group of up to 12 partic-
ipants, with sessions occurring twice weekly for at least 
2 hours (approximately 1 hour for education and 1 hour 
for exercise).
Warm-up and cool-down
Before starting exercises, participants will be taken 
through a group warm up session, followed by a cool down 
session at the end of exercises, each lasting 10–15 min. 
Warm up is aimed at readying the body for both the phys-
ical aspects of performance (increased blood flow and 
muscle temperature) and mental readiness for exercise 
while cool down session facilitates a smoother decline in 
temperature and blood flow20 Both warm up and cool 
down will consist of stretching and flexibility exercises 
during which participants will perform both upper and 
lower body flexibility exercises, held for 10–15 s each 
(including stretching of major muscle groups such as the 
calves, hamstrings, quadriceps and biceps, as well as range 
of motion exercises for the neck, shoulders and trunk), 
2 days/week.13 The cool down session has the same 
activities of warm- up (online supplemental table 1) but 
performed at a slower pace.
Endurance training
Each participant will go through two stations of endur-
ance exercise; load- adjustable stationary cycling and 
ground- based walking stations. We shall employ an inten-
sity of continuous exercise at each station for 10 min or 
until a Borg dyspnoea score of 4–6 (moderate to (very) 
severe) is attained.21 22 Participants who may have diffi-
culty in sustaining continuous high- intensity exercise will 
have interspersed periods of rest or lower intensity exer-
cise to maximise the benefits of exercise training.13 The 
walking exercise regime will be individually prescribed 
to participants based around their performance in the 
ISWT. Participants will be encouraged to walk at 85% of 
their maximal ISWT walking speed.23
Strength training
Each participant will go through two stations for strength-
ening upper limb muscles (pull- ups and biceps curls) and 
two for strengthening lower limb muscles (sit- to- stand 
and step- up exercises). Each of the stations will include 
3 sets of 8–12 repetitions. Participants will be asked to 
continue doing both endurance and resistance exercises 
at home, unsupervised.
Education sessions
A dedicated education session will be conducted at the 




The primary outcome is change in walking distance 
measured by the ISWT from preintervention to postin-
tervention. A group change of at least 35 m is considered 
clinically important.18
Incremental Shuttle Walking Test
The ISWT is frequently used as an outcome measure for 
PR.24 Improvement in walking distance of 35 m during 
the post- PR shuttle test, measured from baseline (pre- PR) 
using the ISWT is considered a clinically important differ-
ence.18 The ISWT requires the patient to walk up and 
down a 10 m course, identified by two cones inset 0.5 m 
from either end to avoid the need for abrupt changes in 
direction. The speed at which the patient walks is dictated 
by an audio signal played on an audio device. Each partic-
ipant will receive standardised instructions to: ‘Walk at a 
steady pace, aiming to turn around when you hear the 
signal. You should continue to walk until you feel that 
you are unable to maintain the required speed without 
becoming unduly breathless’.25 To ensure the learning 
effect is accounted for, a practice ISWT will be performed 
and the participant will receive encouragement from 
the physiotherapist throughout the test in an effort to 
increase the distance one can walk. The test is terminated 
when either (1) the patient indicates that they are unable 
to continue, (2) if the operator determines that the 
Box 1 Education content of the Global RECHARGE 
Pulmonary Rehabilitation programme
1. Normal anatomy and physiology of the lungs.
2. Pathophysiology of chronic lung disease.
3. Tuberculosis and how it causes lung damage.
4. Coping with chronic lung disease and coping with stress.
5. Avoidance of risk factors for chronic lung disease.
6. Early recognition and treatment of exacerbations.
7. Strategies for managing breathlessness.
8. Energy conservation during activities of daily living.
9. Role and rationale for medications and devices.
10. Benefit of exercise and physical activities.
11. Healthy food intake.
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patient is not fit to continue or (3) the operator assesses 
that the patient was unable to sustain the speed and cover 
the distance to the cone prior to the beep sounding.25
Secondary outcomes
All secondary outcomes will be compared between the PR 
and usual care arms from baseline to 6- week and 12- week 
follow- ups.
Health questionnaires will be administered including 
COPD assessment test (CAT), Clinical COPD question-
naire (CCQ), Hospital Anxiety and Depression Scale 
(HADS), Patient Health Questionnaire (PHQ-9), Work 
Productivity and Activity Impairment (WPAI), and Euro-
pean Quality of Life 5- Dimensions (EQ- 5D- 5L). PR- spe-
cific measurements will include the ISWT, Endurance 
Shuttle Walking Test (ESWT), mid upper arm circumfer-
ence and sit- to- stand test.
Respiratory symptoms
The CCQ is a simple 10- time validated HRQoL question-
naire with good psychometric properties.26 It consists of 
10 items, each scored between 0 and 6, divided into three 
domains (symptoms, functional, mental), with higher 
scores representing worse HRQoL. The CCQ is respon-
sive to PR with an estimated minimal important improve-
ment of 0.4.27
The CAT is a validated, self- administered, short and 
simple questionnaire that measures HRQoL.28 The CAT 
consists of eight items, each scored between 0 and 5 
scored with a range of 0–40; scores of 0–10, 11–20, 21–30, 
31–40 representing mild, moderate, severe or very severe 
negative impact on HRQoL, respectively. The CAT is 
responsive to the effects of PR with an estimated minimal 
clinically important difference (MCID) of 2 points.29
Psychological well-being
The HADS questionnaire is a validated, easy to use 
screening tool for anxiety and depression symptoms in a 
hospital outpatient setting.30 The self- report rating scale 
is composed of 14 items with two 7- item subscales (HADS- 
Anxiety and HADS- Depression), both ranging from 0 
to 21 with higher scores indicating more severe distress. 
The HADS is responsive to PR with estimated MCID of 2 
points on each subscale.31 32
The PHQ-9 is a nine item, validated, short, self- 
administered and positively worded questionnaire 
designed to measure the severity of depression over the 
last 2 weeks.33 The total score ranges from 0 to 27, with 
high scores indicating high depression, specifically; no 
depression (0–4), mild (5–9), moderate (10–14), moder-
ately severe (15–19) or severe depression.20–27 33 The 
PHQ-9 has an estimated MCID of 5 points.34
Work productivity and impairment
The WPAI questionnaire is a validated instrument to 
measure impairments in work and activities, both paid 
and unpaid. The WPAI self- administered questionnaire 
measures time missed from work, impairment of work 
and regular activities due to overall health and symptoms, 
during the past 7 days.35 We have added two follow- up 
supplementary questions, following the WPAI format, to 
measure productivity with respect to regular household 
duties in low- resource settings.
Health-related quality of life
The EQ- 5D- 5L questionnaire is a standardised question-
naire, developed to measure of health outcomes and 
defines health in terms of five dimensions: mobility, self- 
care, usual activities, pain or discomfort and anxiety or 
depression.36 The questionnaire also contains a visual 
analogue scale. The EQ- 5D- 5L will be used to calculate 
patient costs per quality- adjusted life- year. EQ- 5D- 5L is 
responsive to change following PR, with a MCID of 0.05 
(utility index) and 7.0 (Visual Analogue Scale).37
Exercise capacity/ physical function
The five- repetition sit- to- stand test (FTSTS) is a commonly 
used functional performance measure of lower- limb 
strength.38 The FTSTS measures the time taken to stand 
five times from a sitting position as rapidly as possible. 
The FTSTS is reliable, valid and responsive to PR with an 
estimated MCID of 1.7 s.39
The MRC dyspnoea scale is a 5- point self- administered 
questionnaire based on the sensation of breathing diffi-
culty experienced by the patient during daily life activi-
ties. The questionnaire is short, easy to use and has grades 
ranging from 1 (none) to 5 (almost compete incapacity), 
with high grades indicating high perceived respiratory 
disability.40 The MRC dyspnoea scale is responsive to PR 
with estimated MCID of 1 points.41 42
The ESWT is a constant- load exercise test which 
measures the ability of the participant to sustain a given 
submaximal exercise capacity; the participant aims to 
walk at 85% of their maximal ISWT walking speed.23 
The ESWT is frequently used as an exercise tolerance 
outcome measure for PR. The endpoint of the test is 
the time the participant walks at the constant endurance 
speed. The test consists of prerecorded audio signals at 
different frequencies giving a total of 16 walking speeds. 
The ESWT is responsive to PR with MCID following a 
6 week PR programme between 174 and 279 s.43
Physical activity
Participants will be asked to wear an ActiGraph wGT3X- BT 
activity monitor (ActiGraph, Pensacola, Florida, USA), 
able to detect a range of PA intensities.44 Participants 
will be instructed to wear the PA monitor on the right 
anterior hip during waking hours for 1 week prior to 
attending PR (preintervention) and for 1 week prior to 
their postintervention assessment (online supplemental 
table 2). Written instructions to follow will be provided 
to the participants prior to wearing and using the PA 
monitors.
Cost/benefit analysis
The cost of starting and running a PR programme will 
include single and recurrent costs (table 2). Single 
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up and run PR. Recurrent costs refer to any item with 
a life expectancy of ≤1 year (eg, disposable materials).45 
The fixed costs will be captured prior to enrolling the first 
participant into the PR programme and the recurrent 
costs will be collected at the mid- stage of recruitment. 
The average fixed and recurrent costs will be calculated 
separately.
Patient and public involvement
Adults with CRDs tell us how they are greatly troubled 
by breathlessness and express interest in attending a 
programme that can help better manage their condi-
tion. They express interest in attending a hospital- based 
programme that allows them to interact with fellow 
patients. They additionally tell us how the PR programme 
should be delivered. We have also set up a patient and 
public involvement group at MLI that will meet regularly, 
and assist with disseminating results following the study.
Data analysis
All randomised participants will be included in the inten-
tion to treat analysis population. The primary efficacy 
analysis will be based on both per protocol and modified 
intention- to- treat populations. For the primary analysis, 
the differences in the primary outcome (walking distance 
on the ISWT) with the corresponding two- sided 95% CI 
and p value will be estimated using a stratified analysis; 
a p<0.05 will be the measure for statistical significance. 
Predictive analytics software (SPSS16) will be used to 
analyse the data. Continuous data will be presented as 
mean and SD or median and IQRs, while categorical 
data will be presented as frequencies and percentages. 
All data will be assessed for normality and appropriate 
parametric and non- parametric tests will be used. Cate-
gorical variables between the two treatment groups will 
be compared using χ2 and Fisher’s exact test as appro-
priate. Continuous variables will be compared using t- test 
for normally distributed data and Mann- Whitney- U test 
for non- normally distributed data. Any baseline differ-
ences will be adjusted for. Both intention- to- treat and 
per- protocol analyses will be conducted after imputing 
any missing data. There will be no formal interim anal-
ysis of data. The final analysis will be performed when all 
the 114 participants have completed the last study related 
visit or previously withdrawn from the trial. We will fit 
linear mixed models for both per- protocol and intention- 
to- treat analyses.
Data management
An independent data monitoring committee will be 
established at the University of Leicester, UK to review 
high level safety data (serious adverse events and adverse 
events) at least quarterly, and as needed on an ad hoc 
basis to ensure the continuing safety of the participants 
enrolled in this study.
All data collected during the trial will be entered into 
the Research Electronic Data Capture46 47 with access via 
a secure password protected web interface hosted by the 
University of Leicester, UK. Study participants will be 
assigned a study- specific identification code.
ETHICS AND DISSEMINATION
The study received ethical approvals from the University 
of Leicester research ethics committee (UK) (Ref No. 
22349) and locally from the Mulago Hospital Research 
and Ethics Committee (MHREC1478), Kampala, Uganda 
as well as the Uganda National Council for Science and 
Technology (SS5105).
Confidentiality
The confidentiality of all participants will be protected to 
the fullest extent possible. All patient information will be 
kept secure and will be available only to the treatment 
staff and representatives of the sponsors, regulators and 
ethics committees.
All participants will be provided with a unique identifi-
cation number which will be recorded in the participant 
enrolment log and stored in a secure place. Study partic-
ipants will not be identified by name on any case report 
Table 2 Table showing the variables used to calculate fixed and recurrent costs (not an exhaustive list)
Fixed costs Recurrent costs
 ► Electrical equipment (laptop, printer, projector)
 ► Equipment for PR (weights, treadmill, cycle ergometer, 
country- specific equipment, step- up box, chairs)
 ► Equipment for shuttle walking tests (cones, licences, stop 
watches, tape measure, electrical equipment to play audio)
 ► Equipment for PR assessment (height stadiometer, weight 
scales, sphygmomanometer, pulse oximeter, spirometer, 
calibration syringe, country- specific equipment)
 ► Additional safety equipment (blood glucose monitor, oxygen 
cylinder holder)
 ► Miscellaneous (filing cabinets, storage units, questionnaire 
translations, questionnaire licences, staff uniform)
 ► Staff time (creating core PR content including educational 
material, exercise diaries and other necessary paperwork)
 ► Staff time to conduct PR (assessment at baseline and discharge, 
conduct PR classes, telephone calls and data entry)
 ► Disposable equipment (for blood glucose monitor, spirometer 
mouthpieces, nose- clips)
 ► Servicing costs (spirometer, PR equipment, specifically cycle 
ergometers)
 ► Miscellaneous (oxygen cylinders, questionnaire licences, 
stationery (paper)
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form, email or on any other documentation sent to the 
central database and will not be reported by name in any 
report, presentation or publication resulting from data 
collected in this study. Participants’ data/specimens will 
be identified by study number or hospital number only.
Dissemination
Results of the study will be published in peer- reviewed 
journals and findings disseminated at appropriate local, 
regional and international scientific meetings and confer-
ences. Social media will be used to disseminate informa-
tion and summaries of results to a wider public domain. 
Furthermore, a participant dissemination meeting will be 
held following this trial, in which study participants will 
receive a summary of the findings.
COVID-19 provisions
Modifications will be made to the delivery of the PR 
programme due to the COVID-19 pandemic. The PR 
room will be reorganised to allow for social distancing 
(minimum 2 m) for both study staff and study partic-
ipants. The maximum number of participants partic-
ipating in the PR session will be reduced from 12 to 8 
to ensure social distancing between participants. Before 
accessing the PR room, all participants and staff will be 
required to undergo temperature measurement using a 
hand- held non- contact thermometer, wash hands with 
soap or alcohol- based hand sanitiser. All participants 
will be provided with face masks during PR sessions. All 
surfaces inside the PR room will be disinfected before 
and after every PR session. PR sessions will be conducted 
in the morning hours to allow participants travel back 
home in time before the evening rush hour and the 
standard operating procedure for data collection will 
be modified ensure 2- metre distancing between the 
study staff and study participant. Study participants will 
undergo COVID-19 testing before starting PR and as 
needed during the hospital based sessions. All study staff 
will be required to wear N95 masks at all times and will 
undergo COVID-19 training with emphasis on infection 
prevention and control, and screening study participants 
for signs and symptoms of the disease.
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Supplementary Table 1: A list of warm up and cool down activities during PR session  
1. Marching on the spot, slowly bringing the feet off the floor for up to 1 minute 
2. Heel digs: alternate heel digs in front of the body with toes pointing to the ceiling, 
add in a biceps curl (repeat 10-12 times). 
3. Toe taps: Tap the toes to the floor in front of alternating legs at a comfortable 
distance. Heels stay off the ground (repeat 10-12 times).  
4. High knee marching – with opposite hand to opposite knee. 
5. Side bends: With arms relaxed by your side, leaning over to the right for 8 to 10 
seconds and back to centre, then lean to the left for 8 to 10 seconds and back to the 
centre (repeat 8 times). 
6. Arms stretched up, forwards and down. 
7. Alternate punching of arms forward. 
8. Seated or standing side taps to the floor with the foot – alternate legs. 
9. Seated or standing in upright posture, feet placed shoulder breadth apart – shoulder 
roll in both directions (clockwise and anti-clockwise). 
10. Seated or standing in upright posture, feet placed shoulder breath apart, elbows bent 
with hands onto shoulder – elbows make circles in clockwise and anti-clockwise. 
11. Hamstring stretch: With right leg straight, place it in front of the body, heel pushed 
into the floor with toes pointing toward the ceiling. Slightly bend the left knee, place 
hands on the straight right leg and gently lean forward. Hold the stretch for 10-15 
seconds then return to upright position. Repeat on left leg. 
12. Quadriceps stretch: While holding a chair or onto a wall, stand on your left leg and 
grab your right foot using your right hand, pulling it gently towards the ceiling. 
Hold the position for 10-15 seconds and return to upright position and repeat on the 
right leg. 
PR – Pulmonary Rehabilitation  
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Supplementary Table 2: Physical activity data collection and accelerometry processing 
criteria 
Criteria Details 
Accelerometer Model ActiGraph wGT3X-BT (version 6.13.4; firmware 1.9.2) 
Serial number range Twenty unique devices will be used; ranging from 
MOS2E09190617 to MOS2E25190750 and averaging six 
deployments per device (same serial used for baseline and 
follow-up wear periods to remove any inter-device variability) 
Piezosensor orientation Triaxial 
Mode setup Mode 29 (x, y, z, steps, lux) 
Original sample rate 100 Hz (.gt3x file format) 
Deployment method Baseline: 
Fitted by research team on Day 0 (Baseline PR Assessment) 
Fitted by participant on Day 1 
Follow-up: 
Fitted by research team Day 0 (11th/12th session) 
Fitted by participant on Day 1 
Location worn Anterior hip adjacent to the mid-line of the thigh 
Requested days of wear 7 days of free-living (10,080 epochs) 
Initialization Not deployed in delay mode in order to standardised capture of 
Day 0 (00:00) with stop time based on date of first PR class 
(baseline) and date of follow-up assessment 
Wear instructions Wear continuously except for sleep and water-based activities 
Non-wear appropriation ≥60 min of consecutive 0s with allowance for 2 minutes of 
interruptions 
Valid day criteria ≥8 hours of valid waking wear time 
Valid file ≥4 valid days for each of the two time points 
Missing data Data modelling or imputation will not be performed 
Epoch length 60 seconds 
Intensity classification 
(absolute) 
Uniaxial (x-axis) intensity cut-points as follows: Stationary 
<100 cpm; Light 100-2019 cpm; Moderate 2020-5998cpm; 
Vigorous ≥5999cpm (Moderate-to-vigorous ≥2020 cpm) 
Intensity classification 
(relative) 
Uniaxial (x-axis) cut-points based on Endurance Shuttle Walk 
Test performance 
PR – Pulmonary Rehabilitation  
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